The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.

AbbVie today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes ...